ABE1971
抗-磷酸TFEB（Ser142）抗体
from rabbit, purified by affinity chromatography
别名:
Transcription factor EB, Ser142 phosphorylated, bHLHe35, Ser142 phosphorylated, Class E basic helix-loop-helix protein 35, Ser142 phosphorylated
biological source
rabbit
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
human
species reactivity (predicted by homology)
rabbit (based on 100% sequence homology), bovine (based on 100% sequence homology), rat (based on 100% sequence homology), mouse (based on 100% sequence homology), nonhuman primates (based on 100% sequence homology)
technique(s)
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
Quality Level
Gene Information
human ... TFEB(7942)
General description
观察值~60 kDa（带有3xFLAG标签）计算分子量为52.87 kDa。某些裂解液可能会出现未表征的条带。
转录因子EB（UniProt P19484；也称为bHLHe35，E类碱性螺旋-环-螺旋蛋白35）由人的TFEB（也称为αTFEB，BHLHE35，TCFEB）基因（基因ID 7942）编码。TFEB是碱性螺旋-环-螺旋（bHLH）亮氨酸拉链转录因子，在溶酶体生物发生的调节中起主要作用。TFEB还是对饥饿转录反应的主要参与者，并通过正向调节自噬体形成和自噬体-溶酶体融合来控制自噬。TFEB在Ser142处被mTORC1和ERK磷酸化，从而阻止了其核易位。mTORC1的药理抑制作用以及饥饿和溶酶体破坏可激活TFEB核易位。类似地，显示丝氨酸-苏氨酸激酶RIP1/RIPK1通过激活ERK抑制基础自噬流，进而使Ser142处的TFEB磷酸化，从而阻止参与自噬的基因产物的TFEB介导的转录。
Immunogen
对应于含有磷酸化Ser142的人TFEB序列的KLH偶联线性肽。
表位：pSer142。
Application
抗磷酸TFEB（Ser142）抗体是一针对磷酸TFEB的抗体，用于蛋白质印迹分析。
蛋白质印迹分析：在RIP1 shRNA处理后，代表性批次在对照HeLa细胞中检测到Ser142磷酸化的TFEB，但在RIP1缺陷型HeLa细胞中未检测到（Yonekawa, T., et al. (2015).Nat. Cell Biol. EMBO Rep.16(6):700-708）。
蛋白质印迹分析：在向营养缺乏的HEK293T转染子中添加氨基酸后，代表性批次检测到外源表达的野生型而非S142A突变体TFEB（具有3xFLAG标签）的Ser142磷酸化诱导（Settembre, C., et al. (2012).EMBO J. 31(5):1095-1108）。
蛋白印迹分析: 代表性批次在饥饿的HeLa转染子中检测到营养诱导的外源表达的TFEB（带有3xFLAG标签）的Ser142磷酸化。mTOR抑制剂Torin1（目录号475991）的预处理完全阻止了营养诱导的TFEB Ser142磷酸化，较弱的mTOR抑制剂雷帕霉素（目录号553210）部分抑制了Ser142磷酸化诱导（Settembre, C., et al. (2012).EMBO J. 31(5):1095-1108）。
蛋白质印迹分析：在向营养缺乏的HEK293T转染子中添加氨基酸后，代表性批次检测到外源表达的野生型而非S142A突变体TFEB（具有3xFLAG标签）的Ser142磷酸化诱导（Settembre, C., et al. (2012).EMBO J. 31(5):1095-1108）。
蛋白印迹分析: 代表性批次在饥饿的HeLa转染子中检测到营养诱导的外源表达的TFEB（带有3xFLAG标签）的Ser142磷酸化。mTOR抑制剂Torin1（目录号475991）的预处理完全阻止了营养诱导的TFEB Ser142磷酸化，较弱的mTOR抑制剂雷帕霉素（目录号553210）部分抑制了Ser142磷酸化诱导（Settembre, C., et al. (2012).EMBO J. 31(5):1095-1108）。
Biochem/physiol Actions
该多克隆抗体仅在表达野生型TFEB的细胞的裂解物中检测到靶带，但在表达具有S142A突变的TFEB的细胞中未检测到靶带（Yonekawa, T., et al. (2015).Nat. Cell Biol. EMBO Rep.16(6):700-708).目标磷酸化位点在鼠（Ser141；UniProt Q9R210）和大鼠（Ser142；UniProt F7F5J1）TFEB蛋白中是保守的，但在人TFEB剪接亚型2（UniProt P19484-2）中不存在。
Analysis Note
通过蛋白质印迹在TFEB转染的HEK293细胞的裂解物中进行了评估。
蛋白质印迹分析：该抗体的1：12500稀释液在转染的HEK293细胞的10 µg裂解物中检测到FLAG标记的人TFEB的Ser142磷酸化。
蛋白质印迹分析：该抗体的1：12500稀释液在转染的HEK293细胞的10 µg裂解物中检测到FLAG标记的人TFEB的Ser142磷酸化。
Other Notes
浓度：请参考特定批次的数据表。
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 2
法规信息
新产品
此项目有
Robert A Brown et al.
Disease models & mechanisms, 12(10) (2019-09-15)
Bi-allelic GBA1 mutations cause Gaucher's disease (GD), the most common lysosomal storage disorder. Neuronopathic manifestations in GD include neurodegeneration, which can be severe and rapidly progressive. GBA1 mutations are also the most frequent genetic risk factors for Parkinson's disease. Dysfunction
Xiaojuan Chao et al.
Alcoholism, clinical and experimental research, 45(10), 1950-1964 (2021-09-07)
Recent evidence demonstrates that alcohol activates the mechanistic target of rapamycin (mTOR) and impairs hepatic transcription factor EB (TFEB) reducing autophagy and contributing to alcohol-induced liver injury. Trehalose, a disaccharide, activates TFEB and protects against diet-induced nonalcoholic fatty liver disease
Hyejin Lim et al.
Nature communications, 9(1), 1438-1438 (2018-04-14)
Autophagy is a critical regulator of cellular homeostasis, dysregulation of which is associated with diverse diseases. Here we show therapeutic effects of a novel autophagy enhancer identified by high-throughput screening of a chemical library against metabolic syndrome. An autophagy enhancer
Xuan Song et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 41(45), 9286-9307 (2021-10-02)
Adult-onset neurodegenerative diseases are often accompanied by evidence of a chronic inflammation that includes activation of microglial cells and altered levels of brain cytokines. Aspects of this response are likely secondary reactions to neurodegeneration, but for many illnesses the inflammation
Hua Shen et al.
Oncogene, 39(49), 7181-7195 (2020-10-11)
The development of resistance to EGFR Tyrosine kinase inhibitors (TKIs) in NSCLC with activating EGFR mutations is a critical limitation of this therapy. In addition to genetic alterations such as EGFR secondary mutation causing EGFR-TKI resistance, compensatory activation of signaling
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持